Leap Therapeutics to Participate at the 43rd Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

Leap Therapeutics (LPTX), a biotechnology company specializing in targeted and immuno-oncology therapeutics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Douglas E. Onsi, the company's President and CEO, will deliver a corporate overview presentation on Wednesday, January 15, 2025, at 2:15 p.m. Pacific Time.

The presentation will be accessible through a live webcast on the Investors page of Leap Therapeutics' website. A replay of the presentation will be available for a time at https://investors.leaptx.com/.

CAMBRIDGE, Mass., Jan. 6, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will present a corporate overview at the 43^rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Leap Presentation Details:

43^rd Annual J.P. Morgan Healthcare Conference
Date: Wednesday, January 15, 2025
Time: 2:15 p.m. Pacific Time

A live webcast of the presentation may be accessed on the Investors page of the company's website at https://investors.leaptx.com/, where a replay of the events will also be available for a limited time.

About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, colorectal, and gynecological cancers. Leap's pipeline also includes FL-501, a humanized monoclonal antibody targeting the growth and differentiation factor 15 (GDF-15) protein, in preclinical development. For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.

CONTACT:

Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com

Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
leap@argotpartners.com  

View original content to download multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-to-participate-at-the-43rd-annual-jp-morgan-healthcare-conference-302336719.html

SOURCE Leap Therapeutics, Inc.

FAQ

When is Leap Therapeutics (LPTX) presenting at the 2025 J.P. Morgan Healthcare Conference?

Leap Therapeutics will present on Wednesday, January 15, 2025, at 2:15 p.m. Pacific Time.

How can investors watch LPTX's presentation at the J.P. Morgan Healthcare Conference?

Investors can watch the presentation via live webcast on Leap Therapeutics' investor relations website at https://investors.leaptx.com/.

Will LPTX's J.P. Morgan Healthcare Conference presentation be available for replay?

Yes, a replay of the presentation will be available for a time on the company's investor relations website.

What type of therapeutics does LPTX develop?

Leap Therapeutics focuses on developing targeted and immuno-oncology therapeutics.

Who will represent LPTX at the 2025 J.P. Morgan Healthcare Conference?

Douglas E. Onsi, President and Chief Executive Officer of Leap Therapeutics, will present the corporate overview.